Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party
2016
Abstrakt
Hematopoietic stem cell transplantation (HSCT) was introduced as treatment for patients with CML in chronic phase (CP) in the late 1970's.1 Transplantation of bone marrow cells from syngeneic donors after high-dose chemotherapy made successful eradication of the Philadelphia positive clone possible. HSCT gained rapid acceptance.